中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents

Value of blood lipid parameters in predicting the progression of HBV-related acute-on-chronic pre-liver failure

DOI: 10.3969/j.issn.1001-5256.2023.07.009
Research funding:

Research Project of Sichuan Provincial Health Commission (20PJ180);

Fundamental Research Funds for the Central Universities (2682021ZTPY022)

More Information
  • Corresponding author: TANG Shanhong, shanhongtang@163.com (ORCID: 0000-0001-6652-2942)
  • Received Date: 2022-10-15
  • Accepted Date: 2022-11-25
  • Published Date: 2023-07-20
  •   Objective  To investigate the difference in blood lipid parameters between acute-on-chronic pre-liver failure (pre-ACLF) and acute-on-chronic liver failure (ACLF) and the risk factors for disease progression.  Methods  A retrospective analysis was performed for the related data of 118 patients with ACLF (ACLF group) and 44 patients with pre-ACLF (pre-ACLF group) who were treated in The General Hospital of Western Theater Command from January 2012 to December 2020, including baseline age, albumin, creatinine, routine blood test results, and blood lipids. The independent samples t-test was used for comparison between normally distributed continuous data; and the Mann-Whitney U test was used for comparison between non-normally distributed continuous data; the chi-square test was used for comparison of categorical data between groups. A binary logistic regression analysis was used for multivariate analysis to identify independent predictive factors. The receiver operating characteristic (ROC) curve was used to compare the sensitivity and specificity of related indicators, and Youden index was used to calculate cut-off values.  Results  Compared with the pre-ACLF group, the ACLF group had significantly lower levels of total cholesterol (TC)[2.02(1.56-2.37) mmol/L vs 3.01(2.57-3.66) mmol/L, Z=5.411, P < 0.001], high-density lipoprotein [0.40(0.25-0.49) mmol/L vs 0.62(0.47-0.75) mmol/L, Z=4.781, P < 0.001], and low-density lipoprotein (LDL) [1.52(1.22-1.84) mmol/L vs 1.93(1.49-2.36) mmol/L, Z=3.146, P=0.002] and significantly higher levels of total bilirubin [352.13(284.32-451.19) μmol/L vs 135.80(112.80-154.68) μmol/L, Z=-9.775, P < 0.001], international normalized ratio [1.96(1.71-2.51) vs 1.39(1.33-1.44), Z=-9.776, P < 0.001], white blood cell count (WBC) [6.74(5.07-9.19)×109/L vs 5.04(4.13-7.09)×109/L, Z=-3.985, P < 0.001], and neutrophils [4.67(3.40-7.06)×109/L vs 3.30(2.72-5.01)×109/L, Z=-3.676, P < 0.001], while there were no significant differences between the two groups in age, creatinine, albumin, alanine aminotransferase, aspartate aminotransferase, and triglyceride (all P > 0.05). The logistic regression analysis showed that TC (odds ratio [OR]=0.003, 95% confidence interval [CI]: 0.000-0.068, P < 0.05), LDL (OR=61.901, 95%CI: 3.354-1142.558, P < 0.05), and WBC (OR=3.175, 95%CI: 1.097-9.185, P < 0.05) had an independent predictive value, and the ROC analysis showed that the area under the ROC curve of TC was 0.852, the sensitivity of LDL was 0.887, and TC had the best specificity of TC was 0.840.  Conclusion  There are reductions in blood lipid parameters in the progression from pre-ACLF to ACLF, suggesting that clinicians should pay attention to the changes in lipids in the pre-ACLF stage and adjust the nutritional regimen in a timely manner.

     

  • loading
  • [1]
    ARTRU F, MCPHAIL M, TRIANTAFYLLOU E, et al. Lipids in liver failure syndromes: A focus on eicosanoids, specialized pro-resolving lipid mediators and lysophospholipids[J]. Front Immunol, 2022, 13: 867261. DOI: 10.3389/fimmu.2022.867261.
    [2]
    LEUTI A, FAZIO D, FAVA M, et al. Bioactive lipids, inflammation and chronic diseases[J]. Adv Drug Deliv Rev, 2020, 159: 133-169. DOI: 10.1016/j.addr.2020.06.028.
    [3]
    HASSE JM. Nutrition and liver disease: complex connections[J]. Nutr Clin Pract, 2013, 28(1): 12-14. DOI: 10.1177/0884533612473156.
    [4]
    LÓPEZ-VICARIO C, CHECA A, URDANGARIN A, et al. Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis[J]. J Hepatol, 2020, 73(4): 817-828. DOI: 10.1016/j.jhep.2020.03.046.
    [5]
    WANG XF, WU WY, QIU GK. et al. Plasma lipidomics identifies novel biomarkers in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Metabolomics, 2017, 13(76). DOI: 10.1007/s11306-017-1215-x.
    [6]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [7]
    MENG QH, HOU W, YU HW, et al. Resting energy expenditure and substrate metabolism in patients with acute-on-chronic hepatitis B liver failure[J]. J Clin Gastroenterol, 2011, 45(5): 456-461. DOI: 10.1097/MCG.0b013e31820f7f02.
    [8]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
    [9]
    WYMANN MP, SCHNEITER R. Lipid signalling in disease[J]. Nat Rev Mol Cell Biol, 2008, 9(2): 162-176. DOI: 10.1038/nrm2335.
    [10]
    GUAN M, TU Y, TANG SH. Classification and research progress of acute-on-chronic liver failure[J]. Chin J Clin Gastroenterol, 2021, 33(6): 450-453. DOI: 10.3870/lcxh.j.issn.1005-541X.2021.06.17.

    官敏, 涂颖, 汤善宏. 慢加急性肝衰竭分型及其研究进展[J]. 临床消化病杂志, 2021, 33(6): 450-453. DOI: 10.3870/lcxh.j.issn.1005-541X.2021.06.17.
    [11]
    YANG C, YANG SH, HU JH, et al. Effect of serum total cholesterol level on the prognosis of patients with liver failure[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31(11): 1053-1056. DOI: 10.3969/j.issn.1005-0264.2021.11.027.

    杨诚, 杨华升, 胡建华, 等. 血清总胆固醇水平对肝衰竭患者预后的影响[J]. 中西医结合肝病杂志, 2021, 31(11): 1053-1056. DOI: 10.3969/j.issn.1005-0264.2021.11.027.
    [12]
    ZHAO J, WANG JH, LI J, et al. Energy metabolism in patients with acute-on-chronic liver failure[J]. Guangdong Med J, 2015, 36(2): 203-207. DOI: 10.13820/j.cnki.gdyx.2015.02.014

    赵娟, 王金环, 李娟, 等. 慢加急性肝衰竭患者的能量代谢状况[J]. 广东医学, 2015, 36(2): 203-207. DOI: 10.13820/j.cnki.gdyx.2015.02.014
    [13]
    ZHANG Z, PEREIRA SL, LUO M, et al. Evaluation of blood biomarkers associated with risk of malnutrition in older adults: a systematic review and meta-analysis[J]. Nutrients, 2017, 9(8): 829. DOI: 10.3390/nu9080829.
    [14]
    WU FP, LI YP, YANG Y, et al. Blood glucose and total cholesterol in the prognosis of patients with liver failure[J]. J Pract Hepatol, 2018, 21(3): 413-416. DOI: 10.3969/j.issn.1672-5069.2018.03.024.

    吴凤萍, 李亚萍, 杨颖, 等. 血糖和总胆固醇水平对肝衰竭患者预后的影响[J]. 实用肝脏病杂志, 2018, 21(3): 413-416. DOI: 10.3969/j.issn.1672-5069.2018.03.024.
    [15]
    DELGADO-COELLO B, BRIONES-ORTA MA, MACÍAS-SILVA M, et al. Cholesterol: recapitulation of its active role during liver regeneration[J]. Liver Int, 2011, 31(9): 1271-1284. DOI: 10.1111/j.1478-3231.2011.02542.x.
    [16]
    GREEN P, THEILLA M, SINGER P. Lipid metabolism in critical illness[J]. Curr Opin Clin Nutr Metab Care, 2016, 19(2): 111-115. DOI: 10.1097/MCO.0000000000000253.
    [17]
    XIAO C, GONG J, ZHU S, et al. Nomogram based on blood lipoprotein for estimation of mortality in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2020, 20(1): 188. DOI: 10.1186/s12876-020-01324-w.
    [18]
    KAWAMOTO M, MIZUGUCHI T, NAGAYAMA M, et al. Serum lipid and lipoprotein alterations represent recovery of liver function after hepatectomy[J]. Liver Int, 2006, 26(2): 203-210. DOI: 10.1111/j.1478-3231.2005.01217.x.
    [19]
    FESSLER MB, PARKS JS. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling[J]. J Immunol, 2011, 187(4): 1529-1535. DOI: 10.4049/jimmunol.1100253.
    [20]
    TRIEB M, RAINER F, STADLBAUER V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure[J]. J Hepatol, 2020, 73(1): 113-120. DOI: 10.1016/j.jhep.2020.01.026.
    [21]
    XU Y, HUANG XP, CHEN L, et al. Value of high-density lipoprotein cholesterol in evaluating the severity and prognosis of hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(7): 1632 -1635. DOI: 10.3969/j.issn.1001-5256.2021.07.030.

    徐英, 黄小平, 陈丽, 等. 高密度脂蛋白胆固醇对HBV相关慢加急性肝衰竭严重程度及预后的预测价值[J]. 临床肝胆病杂志, 2021, 37(7): 1632-1635. DOI: 10.3969/j.issn.1001-5256.2021.07.030.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Article Metrics

    Article views (273) PDF downloads(52) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return